Apricus Biosciences, Inc. (NASDAQ:APRI) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02
|
Departure of Directors or Certain Officers; Election of
Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. |
Directors (the Committee) of Apricus Biosciences, Inc. (the
Company) approved and ratified certain employee bonuses, which were
intended to recognize their efforts related to the Company’s sale
of its ex-US Vitaros business. Special cash bonuses were issued to
the following executive officers and other employees:
|
Name
|
Title
|
Special Cash Bonus
|
|
Richard Pascoe
|
Chief Executive Officer and Secretary
|
$97,479.20
|
|
Brian Dorsey
|
Senior Vice President, Chief Development Officer
|
$63,860.00
|
|
Neil Morton
|
Senior Vice President, Chief Business Officer
|
$55,000.00
|
|
All other employees
|
|
$75,000.00 (in the aggregate)
|
About Apricus Biosciences, Inc. (NASDAQ:APRI)
Apricus Biosciences, Inc. is a pharmaceutical company, which develops pharmaceutical products. The Company primarily focuses on the development and commercialization of products and product candidates in the areas of urology and rheumatology. The Company’s drug delivery technology is a permeation enhancer called NexACT. The Company has over two product candidates in Phase II development, fispemifene for the treatment of symptomatic male secondary hypogonadism and RayVa for the treatment of Raynaud’s phenomenon, secondary to scleroderma. The Company has a commercial product, Vitaros for the treatment of erectile dysfunction (ED), which is in development in the United States, approved in Canada and marketed throughout Europe.